著者

Takaomi Kasuga Asako Sato Tetsuya Babazono

出版者

Society of Tokyo Women's Medical University

雑誌

Tokyo Women's Medical University Journal (ISSN:24326186)

巻号頁・発行日

pp.2022015, (Released:2023-04-27)

参考文献数

30

---

Background: Aortic valve calcification (AVC) has a strong association with cardiovascular outcomes in patients with type 2 diabetics (T2D). The objective of this study was to determine the prevalence and risk factors for AVC in Japanese T2D.Methods: We conducted a cross-sectional study of 193 consecutive T2D with estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73 m2 and without overt heart disease (110 men, mean age 61 years). AVC was determined as bright echoes > 1 mm on at least one cusp of the aortic valve by echocardiography.Results: Eighty-two (42%) diabetic patients had AVC, 9 patients had aortic valve stenosis, and 25 had regurgitation. Patients with AVC were older (67 vs. 55 years), with longer diabetic duration (15 vs. 11 years), lower HbA1c (9.1 vs. 10.0%), higher presence of diabetic retinopathy (66 vs. 47%), lower BMI (24 vs. 26 kg/m2), and lower eGFR (82.1 vs. 90.4 mL/min/1.73 m2) (p < 0.01) than patients without AVC. By logistic regression analysis, older age (p < 0.001) and presence of diabetic retinopathy (p < 0.05) were independent risk factors for AVC in T2D.Conclusions: The prevalence of AVC was 42% in Japanese T2D. Diabetic retinopathy associates with presence of AVC.

著者

坊内 良太郎 馬場園 哲也 花井 豪 岩本 安彦 Ryotaro BOUCHI Tetsuya BABAZONO Ko HANAI Yasuhiko IWAMOTO

出版者

東京女子医科大学学会

雑誌

東京女子医科大学雑誌 (ISSN:00409022)

巻号頁・発行日

vol.81, no.臨時増刊(岩本安彦教授退任記念特別), pp.E135-E140, 2011-03-31 (Released:2012-08-15)

---

(医学部内科学(第三)教室岩本安彦教授退任記念特別号)

著者

Junko Oya Tomoko Nakagami Yuichiro Kondo Aki Katamine Mika Shimizu Yukiko Hasegawa Tetsuya Babazono

出版者

Society of Tokyo Women's Medical University

雑誌

Tokyo Women's Medical University Journal (ISSN:24326186)

巻号頁・発行日

pp.2023008, (Released:2023-11-15)

参考文献数

29

---

Background: To compare the efficacy and safety of pemafibrate with those of fenofibrate in a real-world setting in patients with hypertriglyceridemia and type 2 diabetes (T2D).Methods: This study included 155 patients with hypertriglyceridemia (>175 mg/dL) and T2D. Adjusted least square mean changes in the serum levels of triglycerides (TG), transaminases, γ-glutamyl transpeptidase (γGTP), and estimated glomerular filtration rates (eGFRs) were compared before and after a 3-month therapy with pemafibrate (0.2 mg), fenofibrate (160 mg), or bezafibrate (400 mg). Multivariate logistic regression analyses were performed to examine the association between fibrates, achievement of target TG levels, and deterioration of liver and renal function.Results: Pemafibrate therapy greatly reduced TG levels, which was three times better than fenofibrate therapy in achieving the target range for TG levels. The administration of pemafibrate, not fenofibrate, was significantly associated with a lower risk of increasing γGTP levels. Similarly, a lower risk of eGFR reduction was observed in the pemafibrate group than in the fenofibrate group.Conclusions: Pemafibrate achieved a greater reduction in TG levels toward the desired target range than did fenofibrate. Moreover, pemafibrate was associated with a lower risk profile for elevated γGTP and reduced eGFR than fenofibrate.